đź’ŠExclusive Patent License for CNS Therapeutics by NIH
Prospective Grant of an Exclusive Patent License: Exceptionally Selective D2 Dopamine Receptor Antagonists as Therapeutics
Summary
The National Institute of Neurological Disorders and Stroke and the National Center for Advancing Translational Sciences, institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Psycala Bio, Inc. (Psycala), incorporated in Delaware.
Agencies
- Health and Human Services Department
- National Institutes of Health
Business Impact
$$ - Med
The notice discusses the prospective grant of an exclusive patent license for therapeutic compounds developed for central nervous system disorders. This represents a grant opportunity for Psycala Bio, Inc., but may also impact other companies interested in the field of CNS therapeutics and patent rights through public comments or objections regarding the license.